Keyphrases
Phase II Trial
100%
Previously Treated
100%
Advanced Urothelial Cancer
100%
Weekly Paclitaxel
100%
Median Overall Survival
25%
Advanced Disease
25%
Disease Progression
25%
Systemic Chemotherapy
25%
Confidence Interval
25%
Urothelial Cancer
25%
Paclitaxel
25%
Intravenous Infusion
25%
Hematotoxicity
25%
Median Time
25%
Overall Response Rate
25%
Partial Response
25%
Chemotherapy Regimen
25%
Metastatic Site
25%
Prior Chemotherapy
25%
Time to Progression
25%
Overall Survival Time
25%
Number of Cycles
25%
Nonhematologic
25%
Treatment Refractory
25%
Medicine and Dentistry
Urothelial Cancer
100%
Paclitaxel
100%
Phase II Trials
100%
Disease
20%
Population Research
20%
Disease Exacerbation
20%
Overall Survival
20%
Intravenous Drug Administration
20%
Survival Time
20%
Chemotherapy Regimens
20%
Patient History of Chemotherapy
20%
Chemotherapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Paclitaxel
100%
Phase II Trials
100%
Disease
20%
Chemotherapy
20%
Overall Survival
20%
Disease Exacerbation
20%
Population Study
20%
Survival Time
20%
Patient History of Chemotherapy
20%
Chemotherapy Regimens
20%